Green encapsulants boost stability and sustainability in inverted perovskite solar cells
Yang Y., Zhao J., Yang H., Yang X., Lu Y., Huang Z.
Laboratory Study, published in Nat Commun (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Nat Commun (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41068117
- PMCID
- PMC12511550
- DOI
- 10.1038/s41467-025-64031-8
- Citations
- 2
Abstract (original English)
Perovskite solar cells (PSCs) demonstrate potential for sustainable energy transitions, however their commercialization is impeded by lead toxicity and environmental leakage risks. Herein, it is an effective way to implant a cellulose material with multiple adsorption modes and sites, hydroxypropyl methylcellulose phthalate (HPMCP), which plays a covering role in perovskite crystal and achieves environmental friendliness through effectually suppressing lead leakage. Meanwhile, we have devised a series of multidimensional experimental scheme to assess the impact of lead leakage on the ecosystem from the perspective of cell survival rates and plant growth. HPMCP-modified PSC has a relatively low impact on plant growth and germination, exhibiting a germination rate of 92.3% compared to the blank group (without lead contamination). Moreover, the HPMCP-modified PSCs acquire optimal power conversion efficiency of 26.27% and manifest remarkable environmental stability. This work establishes an environmental and health risk assessment benchmark for PSCs, enabling sustainable deployment.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.